Literature DB >> 28122071

Secukinumab for Acrodermatitis Continua of Hallopeau.

David Muggli1, Julia-Tatjana Maul1, Florian Anzengruber1, Myriam Wyss Fopp2, Alexander A Navarini1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28122071     DOI： 10.1001/jamadermatol.2016.5059

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  3 in total

1.  Highly Resistant Acrodermatitis Continua of Hallopeau and Pustular Psoriasis.

Authors:  John W Frew; Dedee F Murrell
Journal:  Skin Appendage Disord       Date:  2017-04-29

2.  Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau.

Authors:  L M Smirnova; E Yu Vertieva; O Yu Olisova; E M Anpilogova
Journal:  Biologics       Date:  2019-05-20

3.  Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab.

Authors:  María Herrero-Moyano; Tania Marusia Capusan; Constanza Martínez-Mera; Mar Llamas-Velasco; Esteban Daudén
Journal:  JAAD Case Rep       Date:  2018-09-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.